News & Events about Tg Therapeutics Inc.
TG Therapeutics (NASDAQ:TGTX Get Rating) had its price objective raised by Evercore ISI from $16.00 to $25.00 in a research note published on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the biopharmaceutical companys stock. Several other research ...
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active ...
Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PTNEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference...
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics? Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics? PR Newswire NEW YORK, Dec. 30, 2022 NEW YORK, Dec. 30, 2022...